Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epoetin Alfa Increases Cardiovascular Risks When Targeting High Hemoglobin Levels, J&J Study Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients with chronic kidney disease, when treated with a more aggressive dose of Procrit, had a higher risk but no incremental improvement in quality of life.

You may also be interested in...



Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients

Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.

Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients

Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.

J&J Procrit Grows In Q1 Despite Challenges For ESAs

U.S. sales of the erythropoiesis-stimulating agent grew 1 percent in Q1 on strong sales in the hospital and retail market.

Related Content

Topics

UsernamePublicRestriction

Register

PS063381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel